LEADS BIOLABS-B (09887.HK): Oblenio exercises option to retain license for LBL-051, Company to receive USD 10 million

NewTimeSpace News: On 19 August 2026, Nanjing Leads Biolabs Co., Ltd. (stock code: 09887) announced in a voluntary announcement that its subsidiary Leads Biolabs Inc. received a written notice from Oblenio Bio, Inc. (NewCo, a US company founded by Aditum Bio) on 19 August 2026, exercising its option under the cooperation, exclusive option and license agreement (the Oblenio Agreement) dated 5 November 2024 to retain the exclusive global license for LBL-051. Under the agreement, NewCo is required to pay Leads US a one-time, non-refundable and non-creditable fee of USD 10,000,000 upon exercise of the option.

According to the announcement, LBL-051 was discovered and designed based on the Company's proprietary LeadsBodyTM platform, targeting BCMA, CD19 and CD3 simultaneously to achieve broader depletion of pathogenic B cells and plasma cells; this immune reset strategy aims to help patients with multiple refractory autoimmune diseases achieve long-term drug-free remission. Preclinical data presented by NewCo at the European Congress of Rheumatology (EULAR 2026) showed that LBL-051 achieved complete depletion of peripheral and tissue B cells and plasma cells in non-human primate models through stepwise dosing, without triggering cytokine release syndrome (CRS) even at high exposure levels.

The announcement states that the exercise of the option marks an important milestone in the cooperation and lays the foundation for further progress in the global clinical development and commercialization of LBL-051, representing market confidence in the continued clinical progress of the Company's TCE platform in the key therapeutic area of autoimmune diseases. Under Rule 18A.05 of the Listing Rules, the Company cannot guarantee successful development or eventual commercialization of LBL-051.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.